# Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

> **NCT04951778** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 56 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** CC-91633

## Key facts

- **NCT ID:** NCT04951778
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-02
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 56 (ACTUAL)
- **Why stopped:** Efficacy endpoint met; however, overall experimental dosing regimen is not considered optimal to support further clinical development in this patient population
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04951778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04951778, "Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04951778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*